1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C5B37356000CA6FB6525844600457405
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-advocacy-2020-how-top-pharma-manufacturers-effectively-support-advocacy-groups-via-medical-commercial-corporate-teams?opendocument
18
19opendocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Marketing Management Patient Advocacy

Patient Advocacy 2020: How Top Pharma Manufacturers Effectively Support Advocacy Groups via Medical, Commercial and Corporate Teams

ID: PSM-358


Features:

66 Info Graphics

36 Data Graphics

560+ Metrics

41 Narratives


Pages: 117


Published: 2019


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As the pharmaceutical industry gravitates toward increased patient centricity, organizations are embracing novel methods and approaches to develop meaningful relationships with patient advocacy groups.

Consequently, the pharma groups that engage patient advocacy groups continue to evolve and adopt a more collaborative role with the companies’ Medical, Commercial, and Government and Corporate Affairs teams.

Best Practices, LLC conducted benchmarking research to highlight effective practices in patient advocacy group collaboration and relationship management.

This report examines ideal structures and skill sets for pharma groups that deal with advocacy groups, investment and resource levels, regulatory impact, top challenges, and emerging trends that will define the future of successful manufacturer-advocacy collaboration.

Research insights are segmented on the basis of reporting function of benchmark partners to provide a clear understanding of the impact of organizational decisions on patient advocacy trends.

Industries Profiled:
Biopharmaceutical; Biotech; Manufacturing; Clinical Research; Diagnostic; Pharmaceutical; Health Care; Medical Device; Communications; Laboratories


Companies Profiled:
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; AveXis; AVROBIO; Biogen; Bionical Emas; Blue Earth Diagnostics; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Grifols; GlaxoSmithKline ; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; MSD; NexGen Healthcare Communications; OTSUKA; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Theravance; Ultragenyx; Wave Life Sciences

Study Snapshot

Best Practices, LLC engaged 38 leaders supporting patient advocacy at 35 biopharmaceutical companies through a benchmarking survey. More than 70% of benchmark partners are at the director level. At least 70% of benchmark partners are from the United States.

Data in this research is segmented on the basis of reporting structure to offer a clear understanding of the impact of organizational decisions on patient advocacy trends. Research data is presented into the following segments: Total Benchmark Class (N=38), Reports to Commercial (N=10), Reports to Medical Affairs (N=9), Reports to Government and Corporate Affairs (N=13) and Reports to C-Suite (N=6).

Key topics covered in this report include:

  • Understanding the “advocacy” landscape
  • Effective practices for working with potentially hostile patient advocacy groups
  • Preferred advocacy structures
  • Advocacy tools
  • Core competencies of advocacy professionals
  • Advocacy lessons learned from socially sensitive or stigmatized disease areas
  • Profiling advocacy group experience & expertise


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Structuring high performance pharma advocacy groups: Centralized structure dominates with more than a 75% of the benchmark class adopting it. Only 8% have decentralized structure and 16% have hybrid structure. More than 60% of the companies consider their advocacy group structure effective.

  • Managing relationships within controversial/social stigma areas: Develop a structured approach to understand, engage and manage special interest groups in controversial disease state areas. To accomplish this, companies use community awareness programs. Prescriber education, patient education disease awareness websites and public relations also are effective. Be respectful of all advocacy groups’ interests and views to build relationships. It helps to understand group priorities and map points of conflict and common interests. Transparency in interactions helps in building trust, which can be accomplished by communicating regularly and sharing information.

  • Evolving regulatory environment is challenging patient advocacy: Changing regulations are also affecting the patient advocacy landscape. Groups are increasingly getting involved with the FDA. In fact, 76% of partners believe the latest changes in regulations will have high-to-medium impact on patient advocacy strategies. Increasing patient centricity, enabling ease of access, and collaborating will help companies address these regulatory changes.

Table of Contents

I.
Overviewpgs. 3-12
Research Overviewpg. 4
Data Segmentspg. 5
Universe of Learningpg. 6
Patient Advocacypg. 7
Key Recommendationspg. 8
Key Findingspgs. 9-12
II.
Patient Advocacy Functional Structurepgs. 13-24
III.
Patient Advocacy Partner Coordination & Effectivenesspgs. 25-31
IV.
Developing & Optimizing Patient Advocacy Partnershipspgs. 32-40
V.
Managing Relationships Within Controversial Disease Statespgs. 41-50
VI.
Current Trends & Future Directionspgs. 51-55
VII.
Regulatory Impact on Patient Advocacypgs. 56-63
VIII.
Use of Technology, Future Trends & Issuespgs. 64-69
IX.
Ethics and Patient Advocacy Relationspgs. 70-73
X.
Lessons Learnedpgs. 74-82
XI.
Participants’ Profilepgs. 83-85
XII.
Appendixpgs. 86-116
XIII.
About Best Practices, LLCpg. 117

    List of Charts & Exhibits

    I. Patient Advocacy Functional Structure

    • Structure of benchmark companies' patient advocacy function - Total benchmark class
    • Structure of benchmark companies' patient advocacy function - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Efficacy of current structure of patient advocacy function
    • Optimal structure for an internal patient advocacy group along with reasons
    • Interview narrative around company-sponsored summits
    • Ensuring that patient advocacy organizations are able to properly contact or communicate with company’s patient advocacy functional personnel
    • Interview narratives on using Medical Affairs as a contact point
    • Estimated number of FTEs dedicated to patient advocacy activities
    • Benchmark partners’ experience in working on patient advocacy objectives
    • Number of patient advocacy groups currently supported by benchmark companies and expected to support in the coming year - Total benchmark class
    • Number of patient advocacy groups currently supported by benchmark companies and expected to support in the coming year - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite

    II. Patient Advocacy Partner Coordination & Effectiveness

    • Effective metrics for measuring the success of patient advocacy activities and relationships - Total benchmark class
    • Effective metrics for measuring the success of patient advocacy activities and relationships - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Effective approaches designed to coordinate relationships with patient advocacy groups - Total benchmark class
    • Effective approaches designed to coordinate relationships with patient advocacy groups - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Effective methods for prioritizing objectives when a patient advocacy group maintains relationships with multiple brands or therapeutic areas - Total benchmark class
    • Effective methods for prioritizing objectives when a patient advocacy group maintains relationships with multiple brands or therapeutic areas - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite

    III. Developing & Optimizing Patient Advocacy Partnerships

    • Importance of patient advocacy collaborations at different lifecycle stages - Total benchmark class
    • Importance of patient advocacy collaborations at different lifecycle stages - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Most important forms of education, program support, and grants/sponsorships during each of the four key lifecycle stages - Total benchmark class
    • Most important forms of education, program support, and grants/sponsorships during each of the four key lifecycle stages - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Best approaches to deploy advocacy grants/sponsorships for early-stage support with advocacy groups - Total benchmark class
    • Best approaches to deploy advocacy grants/sponsorships for early-stage support with advocacy groups - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Effective strategies for gaining early-stage support with advocacy groups - Total benchmark class
    • Effective strategies for gaining early-stage support with advocacy groups - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite

    IV. Managing Relationships Within Controversial Disease States

    • Interview narrative around demonstrating the benefits of a collaborative relationship to advocacy groups
    • Most critical considerations when managing collaboration with an advocacy group regarding therapies that may trigger controversy or social stigma
    • Interview narrative around identifying critical advocacy characteristics when working in areas with a social stigma
    • Most effective approaches in educating the market on conditions that may be highly controversial or have a social stigma - Total benchmark class
    • Most effective approaches in educating the market on conditions that may be highly controversial or have a social stigma - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Special interest groups’ impact
    • Interview narrative around the key to collaborating on social stigma disease areas
    • Most effective strategies and tactics in minimizing opposition from patient advocacy or other special interest groups against a therapy that could be considered controversial
    • Interview narrative around listening to external partners for achieving success with advocacy groups

    V. Current Trends & Future Directions

    • Interview narrative around developing an advocacy approach depending upon the maturity level of a patient advocacy group
    • Current factors in the marketplace that should receive the greatest consideration with respect to patient advocacy issues
    • Interview narrative around working on the overall negative attitude toward pharma companies
    • Interview narrative around taking inputs into development process from patient advocacy groups

    VI. Regulatory Impact on Patient Advocacy

    • Interview narrative around patient groups’ involvement in drug development
    • Interview narrative around engagement of patient groups in many aspects of clinical studies
    • Funding of clinical trial studies by patient advocacy groups
    • Impact of initiatives such as the 21st Century Cures Act on patient advocacy strategies and tactics to address them - Total benchmark class
    • Impact of initiatives such as the 21st Century Cures Act on patient advocacy strategies and tactics to address them - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Interview narrative around patient groups’ interaction with regulatory agencies
    • Impact of patient involvement in government regulatory agencies, including the FDA and the Prescription Drug User Fee Act on advocacy initiatives within benchmark companies

    VII. Use of Technology, Future Trends & Issues

    • Importance of listed platforms in delivering education to patient groups - Total benchmark class
    • Importance of listed platforms in delivering education to patient groups - Commercial, Medical Affairs, Government and Corporate Affairs, and C-Suite
    • Issues or opportunities foreseen as important for patient advocacy over the next 36 months
    • Interview narrative around understanding external group’s perspective to build effective relationship
    • Maintaining strong relationships with existing advocacy groups, while also expanding to regional groups and providing strong support to national policies

    VIII. Ethics and Patient Advocacy Relations

    • Interview narrative around abiding to ethical boundaries when interacting with patient groups
    • Ethical boundaries adhered to while working with patient advocacy groups
    • Interview narrative on the do’s and don’ts for effective advocacy relationships

    IX. Lessons Learned

    • Interview narrative: Not all patient advocacy groups are effective organizations
    • Most “painful” lessons learned by benchmark partners about relationships with patient advocacy groups
    • Interview narrative around one of the biggest concerns that external cancer advocacy groups have and one of the ways to mitigate it
    • Top success stories about relationships with patient advocacy groups
    • Interview narrative around working with competitors to advance patient welfare
    • Interview narrative around building relations
    • Interview narrative: Patient groups are not always effective in the policy-making process
    • Additional insights in patient advocacy

    X. Participants’ Profile

    • Demographics of benchmark partners
    • Therapeutic area represented by benchmark partners

    XI. Appendix

    • Voices from the field: Optimal structure for an internal patient advocacy group along with reasons
    • Voices from the field: Organization of patient advocacy in a formal structure and improving the structure
    • Voices from the field: Organization of patient advocacy in an informal structure and improving the structure
    • Voices from the field: Top collaboration issues when working with socially sensitive diseases
    • Voices from the field: Best approaches to minimize opposition from special interest groups
    • Voices from the field: Current issues challenging patient advocacy
    • Voices from the field: Impact of new regulations and addressing them
    • Voices from the field: Patient involvement in government regulatory agencies
    • Voices from the field: Future patient advocacy issues and opportunities
    • Voices from the field: Patient advocacy, religious or other special interest groups having a greater impact
    • Voices from the field: Ethical boundaries while working with patient advocacy groups
    • Voices from the field: Painful lessons learned about relationships with patient advocacy groups
    • Voices from the field: Success stories about relationships with patient advocacy groups
    • Voices from the field: Benchmark partners’ experience in working with patient advocacy groups